Wire · operational-macro
US Biotech Investment Curbs May Spare Chinese Licensing Deals But Impede Equity Ties, NewCos
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 27 October 2026 · Fusion42 review
US Treasury proposes outbound investment curbs on biotechnology affecting equity investments and NewCos with China, while licensing-out drug deals remain mostly unaffected. The public feedback period ends Dec. 7, prompting greater scrutiny for Chinese drugmakers in cross-border transactions.
This Wire brief sits within Fusion42's coverage of Biotech.
◆ ◆ The Wire takeaway
US investment rules are tightening on biotech equity and new company deals with China but not on licensing contracts. You need to review your cross-border structures immediately to avoid blocked deals in the US-China biotech corridor.
◆ Coverage
1 source · 27 Oct 2026
◆ Related on Wire
◆ Topics